Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein

Human Gene Therapy

Volumn 15, Issue 3, 2004, Pages 229-238

  De Graaf, Michelle ^a   Pinedo, Herbert M ^a   Oosterhoff, Dinja ^a   Van Der Meulen Muileman, Ida H ^a   Gerritsen, Winald R ^a   Haisma, Hidde J ^b   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GLUCURONIDASE; BUFFER; CELL ADHESION MOLECULE; DOXORUBICIN; HYBRID PROTEIN; N [4 DOXORUBICIN N CARBONYL(OXYMETHYL)PHENYL] 2 BETA GLUCURONYLCARBAMATE; PHOSPHATE; PRODRUG; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CANCER; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLUCURONIC ACIDS; GLUCURONIDASE; HUMANS; MICE; NEOPLASMS; OVARIAN NEOPLASMS; PRODRUGS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SPHEROIDS, CELLULAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 1642305352     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303404322886084     Document Type: Article

References (29)

1. ADAMS, G.P., SCHIER, R., MCCALL, A.M., SIMMONS, H.H., HORAK, E.M., ALPAUGH, R.K., MARKS, J.D., and WEINER, L.M. (2001). High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61, 4750-4755.
2. BOSSLET, K., CZECH, J., and HOFFMANN, D. (1995). A novel one-step tumor-selective prodrug activation system. Tumor Targeting 1, 45-50.
3. BOSSLET, K., STRAUB, R., BLUMRICH, M., CZECH, J., GERKEN, M., SPERKER, B., KROEMER, H.K., GESSON, J.P., KOCH, M., and MONNERET, C. (1998). Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 58, 1195-1201.
4. CHAN, S., GABRA, H., HILL, F., EVAN, G., and SIKORA, K. (1987). A novel tumour marker related to the c-myc oncogene product. Mol. Cell. Probes 1, 73-82.
5. DE BREE, R., ROOS, J.C., QUAK, J.J., DEN HOLLANDER, W., SNOW, G.B., and VAN DONGEN, G.A. (1994). Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract. Nucl. Med. Commun. 15, 613-627.
6. DE GRAAF, M., BOVEN, E., OOSTERHOFF, D., VAN DER MEULEN-MUILEMAN, I.H., HULS, G.A., GERRITSEN, W.R., HAISMA, H.J., and PINEDO, H.M. (2002a). A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br. J. Cancer 86, 811-818.
7. DE GRAAF, M., BOVEN, E., SCHEEREN, H.W., HAISMA, H.J., and PINEDO, H.M. (2002b). Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 8, 1391-1403.
8. EDWARDS, D.P., GRZYB, K.T., DRESSLER, L.G., MANSEL, R.E., ZAVA, D.T., SLEDGE, G.W. Jr., and MCGUIRE, W.L. (1986). Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 46, 1306-1317.
9. FONSECA, M.J., STORM, G., HENNINK, W.E., GERRITSEN, W.R., and HAISMA, H.J. (1999). Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy. J. Gene Med. 1, 407-414.
10. GAZDAR, A.F., CARNEY, D.N., NAU, M.M., and MINNA, J.D. (1985). Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45, 2924-2930.
11. GRILL, J., LAMFERS, M.L., VAN BEUSECHEM, V.W., DIRVEN, C.M., PHERAI, D.S., KATER, M., VAN DER VALK, P., VOGELS, R., VANDERTOP, W.P., PINEDO, H.M., CURIEL, D.T., and GERRITSEN, W.R. (2002). The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol. Ther. 6, 609-614.
12. HAISMA, H.J., BOVEN, E., VAN MUIJEN, M., DE JONG, J., VAN DER VIJGH, W.J., and PINEDO, H.M. (1992). A monoclonal anti-body-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66, 474-478.
13. HAISMA, H.J., VAN MUIJEN, M., SCHEFFER, G., SCHEPER, R.J., PINEDO, H.M., and BOVEN, E. (1995). A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy. Hybridoma 14, 377-382.
14. HAMILTON, T.C., YOUNG, R.C., MCKOY, W.M., GROTZINGER, K.R., GREEN, J.A., CHU, E.W., WHANG-PENG, J., ROGAN, A.M., GREEN, W.R., and OZOLS, R.F. (1983). Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43, 5379-5389.
15. HE, T.C., ZHOU, S., DA COSTA, L.T., YU, J., KINZLER, K.W., and VOGELSTEIN, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
16. HEINE, D., MULLER, R., and BRUSSELBACH, S. (2001). Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy. Gene Ther. 8, 1005-1010.
17. HOUBA, P.H., BOVEN, E., VAN DER MEULEN-MUILEMAN, I.H., LEENDERS, R.G., SCHEEREN, J.W., PINEDO, H.M., and HAISMA, H.J. (2001a). A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: Distribution and efficacy in experimental human ovarian cancer. Br. J. Cancer 84, 550-557.
18. HOUBA, P.H.J., BOVEN, E., VAN DER MEULEN-MUILEMAN, I.H., LEENDERS, R.G.G., SCHEEREN, J.W., PINEDO, H.M., and HAISMA, H.J. (2001b). Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with the monoclonal antibody beta-glucuronidase conjugate. Int. J. Cancer 91, 550-554.
19. HULS, G., GESTEL, D., VAN DER LINDEN, J., MORET, E., and LOGTENBERG, T. (2001). Tumor cell killing by in vitro affinity-matured recombinant human monoclonal antibodies. Cancer Immunol. Immunother. 50, 163-171.
20. KHURI, F.R., NEMUNAITIS, J., GANLY, I., ARSENEAU, J., TANNOCK, I.F., ROMEL, L., GORE, M., IRONSIDE, J., MACDOUGALL, R.H., HEISE, C., RANDLEV, B., GILLENWATER, A.M., BRUSO, P., KAYE, S.B., HONG, W.K., and KIRN, D.H. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
21. KIEVIT, E., PINEDO, H.M., SCHLUPER, H.M., HAISMA, H.J., and BOVEN, E. (1996). Comparison of monoclonal antibodies 17-1A and 323/A3: The influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br. J. Cancer 73, 457-464.
22. KRASNYKH, V., BELOUSOVA, N., KOROKHOV, N., MIKHEEVA, G., and CURIEL, D.T. (2001). Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. 75, 4176-4183.
23. KUPPEN, P.J., VAN DER EB, M.M., JONGES, L.E., HAGENAARS, M., HOKLAND, M.E., NANNMARK, U., GOLDFARB, R.H., BASSE, P.H., FLEUREN, G.J., HOEBEN, R.C., and VAN DE VELDE, C.J. (2001). Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem. Cell Biol. 115, 67-72.
24. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
25. RIETHMÜLLER, G., SCHNEIDER-GADICKE, E., SCHLIMOK, G., SCHMIEGEL, W., RAAB, R., HOFFKEN, K., GRUBER, R., PICHLMAIER, H., HIRCHE, H., PICHLMAYR, R., et al. (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343, 1177-1183.
26. SHINOZUKA, N., KAMISASA, N., AKAISHI, T., MINOSHIMA, T., WATANABE, T., MATSUMOTO, T., ANZAI, H., KOYAMA, I., and KYO, S. (2000). Effect of extra cellular matrix in adenovirus-mediated gene transfer into endothelial cells. Transplant Proc. 32, 983.
27. SOULE, H.D., VAZGUEZ, J., LONG, A., ALBERT, S., and BRENNAN, M. (1973). A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51, 1409-1416.
28. SPOONER, R.A., MARTIN, J., FRIEDLOS, F., MARAIS, R., and SPRINGER, C.J. (2000). In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther. 7, 1348-1356.
29. WEYEL, D., SEDLACEK, H.H., MULLER, R., and BRUSSELBACH, S. (2000). Secreted human beta-glucuronidase: A novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 7, 224-231.